Details of the Drug Reposition

General Information of This Drug (ID: DMLWM4G)

Drug Name
VX-15   DMLWM4G
Synonyms
VX-15/2503; Plexin B1 antagonist (autoimmune disease/cancer), Vaccinex; Anti-CD100 MAb (autoimmune disease/cancer), Vaccinex;Anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Huntington disease DISQPLA4 8A01.10 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 1 [2]
Multiple sclerosis DISB2WZI 8A40 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01764737) Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS. U.S. National Institutes of Health.